Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

Over 22,000 attendees and more than 7,400 abstracts, including a record 265 clinical trial abstracts. This section collects on-site analysis across fifteen signal directions, plus late-breaking, clinical-trial and new-drug abstracts.

NO.01Building↑ 19%
Participants counted21
Heat, past 24h
24h agonow
and 21 other sources reporting·21 participants
65
Heat index
NO.02flat

zoldonrasib

12 sources · 12 participants
54
NO.03flat

elisrasib

6 sources · 6 participants
30

Page 1 No.04–20

  1. 04

    #BREASTCANCER

    22↑ 15%
  2. 05

    HER2Building

    19↑ 17%
  3. 06

    #NSCLC

    18↓ 29%
  4. 07

    #THECHECKPOINTSBuilding

    14↑ 131%
  5. 08

    #PANCREATICCANCERBuilding

    14↑ 28%
  6. 09

    EGFR

    14↓ 29%
  7. 10

    #SPATIALBIOLOGYBuilding

    12↑ 208%
  8. 11

    #PATHOLOGY

    11↓ 29%
  9. 12

    #OVARIANCANCER

    10↓ 29%
  10. 13

    #LUNGCANCER

    9↓ 29%
  11. 14

    pembrolizumab

    8↓ 30%
  12. 15

    TRI-611

    8↓ 29%
  13. 16

    daraxonrasib

    7↓ 29%
  14. 17

    zedoresertib

    7↓ 30%
  15. 18

    ALK

    7↓ 29%
  16. 19

    #MRNA

    7↓ 29%
  17. 20

    #GLIOBLASTOMA

    7↓ 29%
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org